Natera (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 2,264 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Chapman sold 2,264 shares of the business’s stock in a transaction that occurred on Tuesday, October 27th. The stock was sold at an average price of $406.00, for a total value of $919,184.00. Following the transaction, the chief executive officer directly owned 94,662 shares in the company, valued at approximately $38,432,772. This trade represents a 2.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Steven Leonard Chapman also recently made the following trade(s):

• On Wednesday, October 28th, Steven Chapman sold 3,430 shares of Natera stock. The shares were sold at an average price of $426.34, for a total value of $1,462,346.20.
• On Thursday, October 1st, Steven Chapman sold 1,273 shares of Natera stock. The shares were sold at an average price of $413.31, for a total value of $526,143.63.
• On Tuesday, September 1st, Steven Chapman sold 1,698 shares of Natera stock. The stock was sold at an average price of $320.99, for a total value of $545,041.02.
• On Monday, August 3rd, Steven Chapman sold 3,076 shares of Natera stock. The stock was sold at an average price of $266.39, for a total value of $819,415.64.

Natera Trading Up 2.7%

NTRA stock opened at $436.00 on Friday. The firm has a market capitalization of $62.85 billion, a PE ratio of -320.59 and a beta of 1.50. Natera, Inc. has a 1-year low of $181.00 and a 1-year high of $437.41. The business’s 50 day simple moving average is $375.27 and its 200 day simple moving average is $265.54.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The business had revenue of $752.75 million for the quarter, compared to analysts’ expectations of $661.24 million. During the same quarter in the prior year, the business earned ($0.74) EPS. The firm’s revenue for the quarter was up 37.7% on a year-over-year basis. As a group, sell-side analysts predict that Natera, Inc. will post -1.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on NTRA shares. Roth Capital assumed coverage on shares of Natera in a research note on Thursday, October 22nd. They set a “buy” rating and a $475.00 target price for the company. UBS Group lifted their target price on shares of Natera from $290.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, September 9th. Canaccord Genuity Group upped their price target on shares of Natera from $375.00 to $500.00 and gave the company a “buy” rating in a research note on Monday, October 19th. Morgan Stanley increased their price target on shares of Natera from $355.00 to $435.00 and gave the company an “overweight” rating in a report on Monday, October 12th. Finally, Guggenheim increased their price target on shares of Natera from $360.00 to $475.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $394.31.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera presented 25 abstracts at the ESMO oncology conference, highlighting additional Signatera data and supporting the test’s potential commercial and clinical adoption. Natera presents 25 ESMO abstracts
• Positive Sentiment: Investors reacted favorably to Signatera clinical and regulatory wins, which could strengthen Natera’s competitive position in minimal residual disease testing and support future revenue growth. Investors React to Signatera Wins
• Positive Sentiment: The third-quarter outlook centers on continued Signatera volume growth, higher test prices, regulatory progress and expanding Medicare coverage that could benefit Natera’s organ-health business. NTRA Q3 Earnings Preview
• Neutral Sentiment: Natera will release third-quarter 2026 results on November 5 after the market closes, giving investors a near-term catalyst to assess testing volumes, reimbursement trends and profitability. Natera Q3 Results Announcement
• Negative Sentiment: Zacks cautions that Natera may report negative earnings and lacks the typical combination of estimate revisions and momentum associated with a likely earnings beat, raising the risk of volatility around the report. Natera Earnings Beat Outlook
• Negative Sentiment: One valuation analysis estimates NTRA could be about 32% below fair value based on ESMO-related data, suggesting the stock’s gains may have outpaced its fundamentals. Natera Fair Value Analysis
• Negative Sentiment: Two company officers disclosed plans to sell a combined 1,768 shares, including 771 shares valued at approximately $312,000; the transactions are relatively small but may modestly weigh on sentiment. John Fesko Share Sale Solomon Moshkevich Share Sale

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Trust Co. of Vermont acquired a new stake in Natera during the second quarter worth about $26,000. Elevation Wealth Partners LLC bought a new position in Natera in the 2nd quarter valued at about $30,000. Continuum Advisory LLC bought a new position in Natera in the 2nd quarter valued at about $33,000. International Assets Investment Management LLC raised its position in shares of Natera by 132.9% in the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock valued at $35,000 after buying an additional 97 shares in the last quarter. Finally, Rakuten Securities Inc. acquired a new position in shares of Natera in the 2nd quarter valued at approximately $35,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.